Panoptes intends to develop PP-001 up to proof-of-concept studies in humans. For posterior uveitis, a sub-population of uveitis, orphan drug status will be applied which will allow accelerated approvals, financial incentives, higher reimbursement rates and prolonged market exclusivity.
Posterior uveitis will serve as the gateway indication to reach the market rapidly and cost efficiently and will serve as the basis to branch out in other inflammatory and viral indications of high unmet medical need.
Panoptes Pharma is led by a management team with an excellent track record in drug development, documented in particular by the successful transition of several preclinical projects into the clinical stage. The company structure is lean, as most of the operational activities will be outsourced in order to ensure cost efficiency. The experienced senior management team of Panoptes Pharma serves as the intellectual brain and pacemaker of PP-001 development.
The company’s key research and development expertise lies in the rapid transition of preclinical stage projects into proof of efficacy in humans. Panoptes is seeking a strategic partnership with an experienced development and commercialization partner in ophthalmology.
